T. Williamson

发表

Immune cell subset counts associated with graft-versus-host disease.

J. Storek, J. Luider, A. Mansoor, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin.

J. Storek, A. Kalra, F. Khan, 2021, Cytotherapy.

Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin.

D. Mahoney, J. Storek, V. Jimenez-Zepeda, 2019, Blood advances.

Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder.

R. Tellier, J. Storek, V. Jimenez-Zepeda, 2018, Cytotherapy.

High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder.

J. Storek, J. Russell, Yiping Liu, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Risk factors for the incidence of PTLD and the mortality due to PTLD after hematopoietic cell transplantation.

J. Storek, P. Duggan, V. Jimenez-Zepeda, 2021, Transplantation and cellular therapy.

Low Counts of B Cells, Natural Killer Cells, Monocytes, Dendritic Cells, Basophils, and Eosinophils are Associated with Postengraftment Infections after Allogeneic Hematopoietic Cell Transplantation.

J. Storek, J. Luider, A. Mansoor, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Rituximab toxicity after preemptive or therapeutic administration for post-transplant lymphoproliferative disorder.

J. Storek, P. Duggan, A. Kalra, 2022, Transplantation and cellular therapy.

Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low‐dose total body irradiation, and rabbit antithymocyte globulin

J. Storek, P. Duggan, V. Jimenez-Zepeda, 2020, Clinical transplantation.

Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation.

J. Storek, D. Stewart, A. Kalra, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination.

J. Storek, P. Duggan, J. Tay, 2016, Blood advances.

IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD

A. Lyon, J. Storek, J. Russell, 2013, Bone Marrow Transplantation.

Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation.

J. Storek, P. Duggan, N. Bahlis, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG

J. Storek, P. Duggan, N. Bahlis, 2011, Bone Marrow Transplantation.

Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse

J. Storek, A. Grigg, J. Russell, 2013, Bone Marrow Transplantation.

Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients.

K. Fonseca, F. Zhou, J. Storek, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in Thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with Thymoglobulin GVHD prophylaxis

J. Szer, I. Lewis, J. Storek, 2015, Bone Marrow Transplantation.

High incidence of hematologic malignancy relapse after allogeneic transplantation in patients with low Epstein-Barr virus-specific T-cell counts.

R. Tellier, J. Storek, A. Kalra, 2019, Cytotherapy.

Risk factors for post‐transplant lymphoproliferative disorder after Thymoglobulin‐conditioned hematopoietic cell transplantation

R. Tellier, J. Storek, V. Jimenez-Zepeda, 2018, Clinical transplantation.

High Epstein–Barr virus-specific T-cell counts are associated with near-zero likelihood of acute myeloid leukemia relapse after hematopoietic cell transplantation

J. Storek, P. Duggan, A. Ugarte-Torres, 2012, Leukemia.

Fludarabine metabolite level on day zero does not affect outcomes of hematopoietic cell transplantation in patients with normal renal function

C. Griffiths, J. Storek, P. Duggan, 2014, Bone Marrow Transplantation.